middle.news
Mesoblast’s Ryoncil Sales Surge 60% as New US$125M Credit Boosts Growth
10:36am on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
Mesoblast’s Ryoncil Sales Surge 60% as New US$125M Credit Boosts Growth
10:36am on Thursday 29th of January, 2026 AEDT
Key Points
Ryoncil gross sales rose 60% to US$35 million in Q2 FY2026
New US$125 million non-dilutive credit facility at 8% fixed interest secured
Early real-world data show 84% survival in pediatric SR-aGvHD patients treated with Ryoncil
Pivotal adult SR-aGvHD trial expected to begin enrolment soon
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MESOBLAST (ASX:MSB)
OPEN ARTICLE